Welcome to our dedicated page for Neurometrix news (Ticker: NURO), a resource for investors and traders seeking the latest updates and insights on Neurometrix stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neurometrix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neurometrix's position in the market.
NeuroMetrix (NURO) has announced a definitive merger agreement with electroCore (ECOR), where electroCore will acquire NeuroMetrix in a transaction expected to close in late Q1 2025. NeuroMetrix shareholders will receive the company's net cash balance (estimated at approximately $9M) at closing, plus one non-tradeable contingent value right (CVR) per share. The CVR includes rights to future proceeds from any DPNCheck® platform divestiture and royalties up to $500,000 on prescription Quell® product sales over two years post-closing.
The deal requires NeuroMetrix shareholder approval, minimum $8M net cash at closing, and filing of the 2024 Form 10-K. The transaction has received unanimous approval from both companies' Boards of Directors.
NeuroMetrix (NURO) reported Q3 2024 financial results, showing mixed performance. Quell revenue increased 50% to $184,000, while DPNCheck revenue declined 58% to $404,000. Total Q3 revenue was $0.6 million, down 51% year-over-year. The company reported a net loss of $1.5 million ($0.75 per share). Operating expenses were reduced by $0.7 million (25%) through cost-cutting measures. Cash position stands at $14.8 million. The company continues its strategic review process while focusing on building Quell Fibromyalgia business through direct-to-physician marketing and VA facility sales.
NeuroMetrix (Nasdaq: NURO) has reiterated its ongoing review of strategic alternatives to enhance shareholder value, which began in February 2024. Over the past six months, the company has:
1. Evaluated various strategic directions and optimizations
2. Conducted an extensive survey of potential transactions
3. Implemented a substantial reduction-in-force, lowering quarterly operating expenses by over $0.5M
4. Engaged in discussions to sell certain non-core international assets
5. Reported cash and cash equivalents of $16.4M as of June 30, 2024
Despite detailed diligence on multiple opportunities, no suitable transactions have been identified yet. The company believes continuing the strategic review process is in the best interest of shareholders but has not set a completion timeline.
NeuroMetrix reported Q2 2024 financial results and business highlights. Key points include:
1. Quell revenue increased 47% to $192,000, driven by growth in the fibromyalgia indication.
2. DPNCheck revenue declined 62% to $536,000 due to Medicare Advantage changes.
3. The company is proceeding with a De Novo submission for a chemotherapy-induced peripheral neuropathy indication for Quell technology.
4. Q2 2024 net loss was $1.5 million ($0.74 per share) compared to $1.5 million ($1.56 per share) in Q2 2023.
5. The company continues its strategic review process to enhance shareholder value, including exploring asset monetization and reducing operating expenses.
NeuroMetrix (Nasdaq: NURO) has announced its upcoming second quarter 2024 business and financial highlights release, scheduled for August 6, 2024, before the market opens. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results.
Participants wishing to join the call and ask questions should register in advance to receive dial-in information and a unique PIN. An audio-only webcast of the call, along with the earnings press release and financial statements, will be available on the company's website. A replay of the call will be accessible for one year in the Investors section of NeuroMetrix's website.
NeuroMetrix (Nasdaq: NURO) reported its Q1 2024 financial results. The company focuses on reducing neurological disorders and pain syndromes through non-invasive medical devices. Recent efforts include expanding the Board of Directors, reducing equity fundraising, and lowering operating expenses with a smaller workforce.
Quell® Fibromyalgia showed sequential revenue growth, with significant gains in unique prescribers and prescriptions. However, DPNCheck® faced a revenue decline due to Medicare Advantage market challenges.
Q1 2024 revenue was $1.1 million, down 37% from Q1 2023. Gross margin fell to 47%, and operating expenses rose to $3.8 million, resulting in a net loss of $3.0 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.